News & Videos - REGENXBIO INC. - Page 2

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit PR Newswire ROCKVILLE, Md., Oct. 5, 2023 ROCKVILLE, Md. , Oct. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023 . Jefferies CNS/Neuro Summit Presentation Date: Thursday, October 12, 2023 Presentation Time: 2:00 p.m. ET Location: New York, NY A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's...

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society PR Newswire ROCKVILLE, Md., Oct. 3, 2023 RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be well-tolerated in three patients from dose level 1 (1x10 14 GC/kg) Initial biomarker data in two patients who completed three-month...

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society PR Newswire ROCKVILLE, Md., Sept. 26, 2023 ROCKVILLE, Md. , Sept. 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28 th Annual Congress of the World Muscle Society, taking place in Charleston, SC from October 3-7, 2023 . Presentations include interim data from the Phase I/II AFFINITY DUCHENNE™ trial, including longer-term safety and initial microdystrophin...

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Sept. 5, 2023 ROCKVILLE, Md. , Sept. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat Date: Tuesday, September 12, 2023 Fireside Chat Time: 10:10 a.m. ET Location: New York, NY 2023 Baird Global Healthcare Conference Fireside Chat Date: Wednesday,...

Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium PR Newswire ROCKVILLE, Md., Aug. 30, 2023 Six-month data from single-patient, investigator-initiated trial showed that one-time administration of RGX-181 was well tolerated, achieved sustained gene expression and demonstrated clinically meaningful improvements across multiple measures including reduced (86%) seizure frequency. Investigators observed encouraging neurodevelopmental skill...

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 PR Newswire ROCKVILLE, Md., Aug. 23, 2023 ROCKVILLE, Md. , Aug. 23, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 in Jerusalem, Israel ( August 29 – September 1 ). Investigators will deliver encore presentations of interim clinical trial data from REGENXBIO's...

REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Aug. 2, 2023 Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 ABBV-RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie Interim results from Phase II AAVIATE ® and ALTITUDE ® trials of...

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference PR Newswire ROCKVILLE, Md., Aug. 1, 2023 ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, June 8, 2023 . 2023 Wedbush PacGrow Healthcare Conference Date: Tuesday, August 8, 2023 About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company...

REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., July 26, 2023 ROCKVILLE, Md. , July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 2, 2023 , at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023 , and recent operational highlights. Listeners can register for the webcast via this...

REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting PR Newswire ROCKVILLE, Md., July 24, 2023 ROCKVILLE, Md. , July 24, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced three presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, taking place in Seattle, Washington from July 28 through August 1, 2023 . The presentations will highlight data for ABBV-RGX-314, an investigational...

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023 PR Newswire ROCKVILLE, Md., July 11, 2023 -Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation - Initial safety results from Cohort 1 of the AFFINITY DUCHENNE study support well-tolerated profile to date; initial efficacy data to be...

REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates PR Newswire ROCKVILLE, Md., June 27, 2023 -REGENXBIO AAV Therapeutics pipeline to be discussed by management and external experts -Focus on programs for Wet AMD, Diabetic Retinopathy, and Duchenne Muscular Dystrophy ROCKVILLE, Md. , June 27, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a virtual investor day on July 11, 2023 . During the event,...

REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit PR Newswire ROCKVILLE, Md., June 20, 2023 ROCKVILLE, Md. , June 20, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it has filed a second complaint for patent infringement against Sarepta Therapeutics, Inc. (Sarepta) arising from Sarepta's manufacture, use and imminent commercial launch of SRP-9001 for the treatment of Duchenne muscular dystrophy. The complaint asserted U.S. Patent...

REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference PR Newswire ROCKVILLE, Md., June 1, 2023 ROCKVILLE, Md. , June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 . Jefferies Global Healthcare Conference Date: Thursday, June 8, 2023 Presentation: 1:30 p.m. ET A live webcast of the presentation can be accessed in the...

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome PR Newswire ROCKVILLE, Md., May 23, 2023 RMAT recognizes that the preliminary clinical evidence from RGX-121, a potential one-time AAV Therapeutic, indicates the potential to address unmet medical needs for MPS II RMAT designation is for gene therapies intended to treat or cure serious condition in order to expedite the drug development and review processes CAMPSIITE™...

REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023 PR Newswire ROCKVILLE, Md., May 22, 2023 ROCKVILLE, Md. , May 22, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023 . Barclays Gene Editing & Therapy Summit 2023 Date: Wednesday, May 24, 2023 Fireside Chat: 9:15 a.m. ET Panel:...

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio PR Newswire ROCKVILLE, Md., May 16, 2023 Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV ® Technology licenses will support development of gene therapies for rare diseases ROCKVILLE, Md. , May 16, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS...

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., May 8, 2023 ROCKVILLE, Md. , May 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Fireside Chat Date: Wednesday, May 10, 2023 Fireside Chat Time: 5:00 p.m. PT Location: Las Vegas, NV RBC 2023 Global Healthcare Conference Fireside Chat Date: Tuesday, May 16, 2023 Fireside Chat...

REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., May 3, 2023 Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 Announced Updates to Eye Care Collaboration with AbbVie Investigational gene therapy renamed ABBV-RGX-314 IND sponsorship recently transferred to AbbVie for all ongoing clinical trials...

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting PR Newswire ROCKVILLE, Md., May 2, 2023 ROCKVILLE, Md. , May 2, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place in Los Angeles, California from May 16 through 20, 2023 . The presentations highlight the Company's end-to-end capabilities across clinical development and research...